Arizona Clinical Trials Report — April 2026

For Arizonans considering participation in clinical research, April 2026 brings an urgent call to action, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 107 clinical trials are slated to close within the next 90 days. This critical window of opportunity extends to healthy volunteers, with 15 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on neurological conditions, chronic pain, and age-related issues are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Myasthenia gravis
• Migraine
• Atopic dermatitis
• Mild cognitive impairment
• Aging
• Obesity
• Alzheimer disease
• Asthma
• Major depressive disorder
• Acute lymphoblastic leukemia

Major Advancements: New Phase 2 and 3 Trials Launching in Arizona

This month, Arizona welcomes 7 new clinical trials, offering participants the chance to engage with cutting-edge treatments and diagnostic tools. While the total number of new trials is lower than the 19 that opened in March 2026, several significant Phase 2 and 3 studies from major pharmaceutical companies have launched, addressing a range of health challenges from advanced cancers to dermatological conditions.

Among the most notable new opportunities are:

• Incyte Corporation is sponsoring NCT07522073, a pivotal Phase 3 study. This trial evaluates chemotherapy with or without the investigational drug INCB161734 in individuals with previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial aims to enroll 588 participants, offering a potential new approach for a challenging cancer.
• Priovant Therapeutics, Inc. is initiating NCT07532603, a Phase 2/3 study focused on lichen planopilaris. This research will evaluate the clinical safety and efficacy of oral brepocitinib in participants with this inflammatory hair loss condition, with a target enrollment of 342 individuals.
• Eli Lilly and Company has launched NCT07533019, a Phase 2 study investigating LY4005130 in adult participants with non-segmental vitiligo (NSV). This trial, designed for 60 participants, will assess the tolerability and side effects of the study drug administered intravenously, compared to a placebo.

Beyond these major drug trials, other new studies are exploring a diverse set of conditions, including child mental health, developmental language disorder, interparental conflict, and kidney stones. These trials represent a mix of drug, behavioral, device, and other research types, reflecting a broad approach to medical innovation.

Arizona's Research Footprint: Where New Trials Are Opening

Arizona's clinical research landscape remains robust, with a total of 1,686 clinical trials currently recruiting across 43 cities and 1,136 research sites statewide. This wide distribution ensures accessibility for many residents interested in participation.

This month, new trial openings were concentrated in several key areas:

• Phoenix (4 new trials)
• Chandler (1 new trial)
• Flagstaff (1 new trial)
• Tempe (1 new trial)
• Tucson (1 new trial)

While Phoenix continues to be a hub for new research, the presence of new trials in Flagstaff, Chandler, Tempe, and Tucson demonstrates a commitment to expanding research opportunities beyond the immediate metropolitan core.

Participation Opportunities: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 7 new trials launched this month, 3 include children, and 6 are open to older adults, ensuring that diverse age groups have opportunities to contribute to medical science. No new trials this month are exclusively for female or male participants.

For individuals without a specific medical condition, there are numerous opportunities to contribute. While none of the 7 new trials this month are specifically seeking healthy volunteers, a total of 147 clinical trials statewide are currently recruiting healthy participants. These studies play a crucial role in understanding normal bodily functions, testing new diagnostics, and establishing baseline data for future treatments.

Academic institutions and industry sponsors both contribute significantly to Arizona's research ecosystem. This month, 4 new trials are sponsored by industry leaders like Eli Lilly and Company, Incyte Corporation, and Priovant Therapeutics, Inc., while 3 trials are supported by academic and other research organizations, including Northern Arizona University and NYU Langone Health.

As we move through April, the focus remains on the ongoing enrollment in these significant Phase 2 and 3 trials, alongside the critical need for participants in studies nearing their closing dates. Exploring these options now can connect you with opportunities to contribute to future medical breakthroughs in Arizona and beyond.